Diabetic cardiomyopathy - A comprehensive updated review

Diabetes causes cardiomyopathy and increases the risk of heart failure independent of hypertension and coronary heart disease. This condition called “Diabetic Cardiomyopathy” (DCM) is becoming a well- known clinical entity. Recently, there has been substantial research exploring its molecular mechan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Progress in cardiovascular diseases Jg. 62; H. 4; S. 315 - 326
Hauptverfasser:	Murtaza, Ghulam, Virk, Hafeez Ul Hassan, Khalid, Muhammad, Lavie, Carl J., Ventura, Hector, Mukherjee, Debabrata, Ramu, Vijay, Bhogal, Sukhdeep, Kumar, Gautam, Shanmugasundaram, Madhan, Paul, Timir K.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States Elsevier Inc 01.07.2019
Schlagworte:	Biomarkers - blood Cardiac Imaging Techniques - methods Cardiomyopathy Cardiovascular Comorbidity Diabetes Diabetes Mellitus - diagnosis Diabetes Mellitus - epidemiology Diabetes Mellitus - therapy Diabetic Cardiomyopathies - diagnostic imaging Diabetic Cardiomyopathies - epidemiology Diabetic Cardiomyopathies - therapy Diastolic dysfunction Early Diagnosis Ejection fraction Female Heart failure Heart Failure - diagnostic imaging Heart Failure - epidemiology Heart Failure - therapy Humans Male Mass Screening - methods Prognosis Risk Assessment Risk factors Survival Analysis FFA eNOS LVM NPADH-oxidase BNP Cardiomyopathy NF-kB RAAS DPP-4 DM LV Risk factors LVEDP α-SMA TZDs VLDL EMB RNV MCFAs Heart failure EF CAD G-SPECT LGE MAPK DCM SGLT-2 CVD CAN ARNI BBs MMP-2 ROS TGL GLP-1R Ejection fraction Vaspin NO HTN miRNAs MRI RyR HFpEF CoQ 10 HFrEF AAs VHD ACEI TDI TGF-β IBT PI3Kg SR VEGF AGEs RAGE ECM Diastolic dysfunction Diabetes ARBs HbA1C CHD HF PET LVH matrix metalloproteinase-2 Receptor for advanced glycation end products angiotensin receptor and neprilysin inhibitor incretin-based therapies medium-chain fatty acids cardiac autonomic neuropathy dipeptidyl peptidase-4 nuclear factor kappa-light-chain-enhancer of activated B cells left ventricular end diastolic pressure nitric oxide Gated Single Photon Emission Computed Tomography coenzyme Q10 free fatty acids Late-gadolinium enhancement beta blockers mitogen-activated protein kinase valvular heart disease cardiovascular disease angiotensin receptor blockers angiotensin converting enzyme inhibitors triglycerides Coronary artery disease glycated hemoglobin coronary heart disease Thiazolidinediones extracellular matrix radionuclide ventriculography left ventricle brain natriuretic peptide Ryanodine receptors diabetic cardiomyopathy sarcoplasmic reticulum renin-angiotensin-aldosterone system endothelial nitric oxide synthase Vascular endothelial growth factor heart failure Visceral adipose tissue–derived serine protease inhibitor nicotinamide adenine dinucleotide phosphate oxidase system left ventricular hypertrophy endomyocardial biopsy very low density lipoprotein Glucagon-like peptide-1 receptor magnetic resonance imaging Tissue Doppler Imaging ejection fraction diabetes mellitus advanced glycation end products left ventricular mass Phosphoinositide3-kinase gamma heart failure with preserved ejection fraction reactive oxygen species heart failure with reduced ejection fraction transforming growth factor–β MicroRNAs aldosterone antagonists positron emission tomography smooth muscle actin hypertension sodium-glucose transporter-2
ISSN:	0033-0620, 1873-1740, 1532-8643, 1873-1740
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Diabetes causes cardiomyopathy and increases the risk of heart failure independent of hypertension and coronary heart disease. This condition called “Diabetic Cardiomyopathy” (DCM) is becoming a well- known clinical entity. Recently, there has been substantial research exploring its molecular mechanisms, structural and functional changes, and possible development of therapeutic approaches for the prevention and treatment of DCM. This review summarizes the recent advancements to better understand fundamental molecular abnormalities that promote this cardiomyopathy and novel therapies for future research. Additionally, different diagnostic modalities, up to date screening tests to guide clinicians with early diagnosis and available current treatment options has been outlined.
Bibliographie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23
ISSN:	0033-0620 1873-1740 1532-8643 1873-1740
DOI:	10.1016/j.pcad.2019.03.003